Insulet Corporation PODD was a big mover last session, as the company saw its shares rise nearly 9% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $117.93 to $155.19 in the past one-month time frame.
The company has seen nine negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
Insulet currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Insulet Corporation Price
Insulet Corporation price | Insulet Corporation Quote
Investors interested in the Medical - Products industry may consider Eagle Pharmaceuticals, Inc. EGRX, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is PODD going up? Or down? Predict to see what others think: Up or Down
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
See 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Insulet Corporation (PODD) : Free Stock Analysis Report
Eagle Pharmaceuticals, Inc. (EGRX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research